Search the Studies

456 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
000486-CA Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI
000475-CPhase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)Participants currently recruited/enrolled18-125 YearsNCI
000359-CPhase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignanciesRecruitment has not started12-85 YearsNCI
000337-CNatural History Study of KSHV-Associated Multicentric Castleman s DiseaseRecruitment has not started18-125 YearsNCI
000328-CBicalutamide Implants (Biolen (Registered Trademark)) with Radiation Therapy in Patients with Localized Prostate CancerRecruitment has not started18-125 YearsNCI
000302-CNatural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesRecruitment has not started18-125 YearsNCI
000293-CManaging Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed with a Primary Brain TumorEnrolling by Invitation18-125 YearsNCI
000264-CA Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseParticipants currently recruited/enrolled18-125 YearsNCI
000254-CA Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)Participants currently recruited/enrolled18-125 YearsNCI
000251-CThe Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)Participants currently recruited/enrolled18-125 YearsNCI
000194-CA Phase I Trial of ProAgio, an anti- alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor MalignanciesRecruitment has not started18-125 YearsNCI
000193-CPhase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell LymphomasRecruitment has not started18-125 YearsNCI
000176-CA Phase I/II Trial of Lurbinectedin with Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine CancersParticipants currently recruited/enrolled18-125 YearsNCI
000173-CSystematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement from Photographs of Subjects with Neurofibromatosis Type 1 on a Phase 2 Clinical TrialParticipants currently recruited/enrolled7-125 YearsNCI
000144-CA Phase I/II Study of Sacituzumab Govitecan plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsRecruitment has not started18-125 YearsNCI
000115-CA Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor TherapyParticipants currently recruited/enrolled18-125 YearsNCI
000103-CA Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersRecruitment has not started18-125 YearsNCI
000096-CA Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck CancerRecruitment has not started18-125 YearsNCI
000092-CPhase 1/2 study of Vincristine and Temozolomide in Combination with PEN-866 for Adolescents and Young Adults with Relapsed or Refractory Solid TumorsRecruitment has not started12-39 YearsNCI
000085-CAssessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: an Observational StudyEnrolling by Invitation18-125 YearsNCI
000081-CA Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell SarcomaParticipants currently recruited/enrolled2-125 YearsNCI
000067-CUnderstanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell TherapyParticipants currently recruited/enrolled2-125 YearsNCI
000059-CPhase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant MesotheliomaParticipants currently recruited/enrolled18-125 YearsNCI
000057-CA Phase 1 Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to DocetaxelParticipants currently recruited/enrolled18-125 YearsNCI
000048-CA Multi-Center Natural History Study of Precision-Based Genomics in Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
000021-CPhase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR-105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell TransplantParticipants currently recruited/enrolled4-125 YearsNCI
21-C-0026A Phase I/II Study of Abemaciclib in Patients with HIV-associated and HIV-negative Kaposi SarcomaRecruitment has not started18-125 YearsNCI
21-C-0024A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple MyelomaRecruitment has not started18-125 YearsNCI
21-C-0023A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIVRecruitment has not started18-125 YearsNCI
21-C-0022A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaRecruitment has not started16-75 YearsNCI
21-C-0021SARC037: A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) ImagingParticipants currently recruited/enrolled10-125 YearsNCI
21-C-0019Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and VariantRecruitment has not started18-125 YearsNCI
21-C-0017Magnetic Resonance Image (MRI) Guided High Energy Ultrasound for Focal Prostate Cancer AblationRecruitment has not started18-125 YearsNCI
21-C-0015Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or GliosarcomaRecruitment has not started18-125 YearsNCI
21-C-0014Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI
21-C-0013A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory PapillomatosisParticipants currently recruited/enrolled18-125 YearsNCI
21-C-0012Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesParticipants currently recruited/enrolled18-125 YearsNCI
21-C-0011A Phase I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical NeurofibromasRecruitment has not started12-125 YearsNCI
21-C-0009A Natural History Study of Children and Adults with Olfactory NeuroblastomaRecruitment has not started3-125 YearsNCI
21-C-0007Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients with Advanced CancerRecruitment has not started18-125 YearsNCI
21-C-0006Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in CholangiocarcinomaRecruitment has not started18-125 YearsNCI
21-C-0004Phase I/II Evaluation of Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients with Unresectable Pulmonary Metastases from Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesRecruitment has not started18-125 YearsNCI
21-C-0001A Phase I/II Study of Bintrafusp alfa (M7824) and M9241 in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0169A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaRecruitment has not started18-125 YearsNCI
20-C-0167Close Assessment and Testing for Chronic Graft-vs-Host Disease (CATCH Study)Participants currently recruited/enrolled18-125 YearsNCI
20-C-0164Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Selection and Disease Progression in Patients Undergoing Active Surveillance for Prostate CancerRecruitment has not started18-125 YearsNCI
20-C-0162A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesRecruitment has not started18-125 YearsNCI
20-C-0161Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisParticipants currently recruited/enrolled6-125 YearsNCI
20-C-0155Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)Participants currently recruited/enrolled18-125 YearsNCI
20-C-0154Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0152Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).Participants currently recruited/enrolled18-125 YearsNCI
20-C-0150Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation CarriersRecruitment has not started18-125 YearsNCI
20-C-0149Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors.Participants currently recruited/enrolled18-125 YearsNCI
20-C-0142A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0139Natural History Study of Children and Adults with Neuroendocrine Neoplasms (NENs)Participants currently recruited/enrolled3-125 YearsNCI
20-C-0138Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0134A Phase II basket trial of glutaminase inhibitor (BEGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 mutant malignant peripheral nerve sheath tumors (MPNST), KEAP1/NRF2 and LKB1 aberrant tumorsParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0130A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor PainEnrolling by Invitation12-125 YearsNCI
20-C-0127A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignanciesParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0121Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelParticipants currently recruited/enrolled18-120 YearsNCI
20-C-0116A Pilot Study of E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical CancerClinical hold/Recruitment or enrollment suspended18-125 YearsNCI
20-C-0110Natural History Study of Children and Adults with Adrenocortical CancerParticipants currently recruited/enrolled2-125 YearsNCI
20-C-0107Clinical, Genetic, and Epidemiologic Study of Children and Adults with RASopathiesParticipants currently recruited/enrolled0-125 YearsNCI
20-C-0106Prospective Evaluation of Photon Counting Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition SyndromeParticipants currently recruited/enrolled30-125 YearsNCI
20-C-0104Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive CancersParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0103Investigation of the B- and T-cell Repertoire and Immune Response in Patients with Acute and Resolved COVID-19 InfectionParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0098A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0097A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0076Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600E Mutated Relapsed/Refractory HCLParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0075Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0074A Phase I/II Study of the Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Advanced Pancreas Cancer.Participants currently recruited/enrolled18-125 YearsNCI
20-C-0070A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients with Primary Immunodeficiency DiseasesParticipants currently recruited/enrolled4-69 YearsNCI
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0065A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) PatientsParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0062A Phase Ib Study of Nivolumab in Patiaents with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)Participants currently recruited/enrolled18-125 YearsNCI
20-C-0061Phase I/II of NHS-IL12 Monotherapy and in Combination with M7824 in Advanced Kaposi SarcomaParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0058A Pilot Study of Front Line Ibrutinib for Newly Diagnosed Chronic Graft-Versus-Host DiseaseParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0056A Phase 1b Trial of Sequential Combinations of BN-Brachyury, Entinostat, ado-trastuzuamb emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)Participants currently recruited/enrolled18-125 YearsNCI
20-C-0051Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Genitourinary Malignancies Branch StudiesParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0045Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0043THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients with Advanced Pancreatic CancerRecruitment has not started18-99 YearsNCI
20-C-0042A Phase II Pilot Trial to Estimate Survival After A Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-GeneratioParticipants currently recruited/enrolled3-30 YearsNCI
20-C-0041Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic InjuriesParticipants currently recruited/enrolled0-125 YearsNCI
20-C-0035A Phase I/II open-Label, Multi-Center, Dose-escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-ligand Therapy in Patients with Prostate Specific Membrane Antigen (PSMA) Positive (68No longer recruiting/follow-up only18-125 YearsNCI
20-C-0028Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid LeukemiaParticipants currently recruited/enrolled3-35 YearsNCI
20-C-0027A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed GlioblastomaParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0024A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus InfectionClinical hold/Recruitment or enrollment suspended18-125 YearsNCI
20-C-0023First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid TumorsParticipants currently recruited/enrolled12-125 YearsNCI
20-C-0022Phase II Trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)Participants currently recruited/enrolled18-125 YearsNCI
20-C-0020Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) specimens using Modified Existing Surgical Resectoscope DeviceParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0015A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081 in Subjects with Advanced Stage Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI
20-C-0013Phase I/II trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers.Participants currently recruited/enrolled18-125 YearsNCI
20-C-0012A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0011Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeNo longer recruiting/follow-up only18-125 YearsNCI
20-C-0010Phase II Trial of Radium-223 in Biochemically Recurrent Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0009Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung CancerParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0008T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell malignancies and Hodgkin LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI
20-C-0007Phase II Trial of Avelumab (Bavencio) with IL-15 in Subjects with Clear-Cell Renal CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI
20-C-0006A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC).Participants currently recruited/enrolled18-125 YearsNCI
20-C-0001Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients with Advanced CancerCompleted Study; data analyses ongoing18-125 YearsNCI
19-C-0143A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic CancerClinical hold/Recruitment or enrollment suspended18-70 YearsNCI
19-C-0142Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell DonorsEnrolling by Invitation5-125 YearsNCI
19-C-0138Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)Recruitment has not started18-125 YearsNCI
19-C-0137A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)Participants currently recruited/enrolled18-125 YearsNCI
19-C-0136A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (CGVHD) After at Least 2 Prior Lines of Systemic TherapyParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0135Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsParticipants currently recruited/enrolled12-125 YearsNCI
19-C-0134A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following ChemotherapyParticipants currently recruited/enrolled60-125 YearsNCI
19-C-0132Incidental Detection of Maternal Neoplasia Through Non-invasive Cell-Free DNA Analysis (IDENTIFY), a Natural History StudyParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0131Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)Participants currently recruited/enrolled5-125 YearsNCI
19-C-0129A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal CarcinomatosisParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0128A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0127A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults with Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Participants currently recruited/enrolled18-125 YearsNCI
19-C-0122A Phase II Study of E7 TCR T Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal CancerClinical hold/Recruitment or enrollment suspended18-125 YearsNCI
19-C-0119An Open-Label, Multicenter Rollover Study to Provide Continued Treatment with Anetumab Ravtansine For Participants with Solid Tumors Who Were Enrolled in Previous Bayer-Sponsored Studies.Enrolling by Invitation18-125 YearsNCI
19-C-0117A Phase 1 / 2 Single Arm Open-label Clinical Trial of TC-210 T-Cells in Patients with Advanced Mesothelin Expressing CancerParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0116A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0112Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic MalignanciesParticipants currently recruited/enrolled12-65 YearsNCI
19-C-0104A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0103A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)Participants currently recruited/enrolled18-125 YearsNCI
19-C-0102A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple MyelomaCompleted Study; data analyses ongoing18-73 YearsNCI
19-C-0096Studying the Biology of IDH-mutant Gliomas via Longitudinal Observation of 2-Hydroxyglutarate (2-HG) using MR SpectroscopyParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0094A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC)Participants currently recruited/enrolled18-125 YearsNCI
19-C-0085Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell LymphomaParticipants currently recruited/enrolled12-125 YearsNCI
19-C-0082Natural History Study of Children and Adults with ChordomaParticipants currently recruited/enrolled2-125 YearsNCI
19-C-0076A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies.No longer recruiting/follow-up only18-125 YearsNCI
19-C-0062A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0061A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorsParticipants currently recruited/enrolled12-125 YearsNCI
19-C-0049Long Term Follow-up of Mesothelioma Patients and Their Family Members with Germline Mutations in BAP1 and Other GenesParticipants currently recruited/enrolled2-125 YearsNCI
19-C-0042A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Rituximab (Rituxan (R)) for Relapsed Hairy Cell LeukemiaParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0041Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)Participants currently recruited/enrolled18-99 YearsNCI
19-C-0040Natural History Study of Men at High Genetic Risk for Prostate CancerParticipants currently recruited/enrolled30-75 YearsNCI
19-C-0039Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0038An Open-Label, First-in-Human, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of a Thorium-227 Labeled Antibody-Chelator Conjugate, BAY 2287411/18795 Injection, in Patients with Solid Tumors Known to ExpNo longer recruiting/follow-up only0-125 YearsNCI
19-C-0033Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic CancersParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0030A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular LymphomaParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0025Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic MalignanciesRecruitment has not started18-125 YearsNCI
19-C-0024Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0023A Phase II Study of Olaparib in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair DefectsParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0017A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsClinical hold/Recruitment or enrollment suspended18-70 YearsNCI
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled1-125 YearsNCI
19-C-0011Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord EpendymomaCompleted Study; data analyses ongoing0-125 YearsNCI
19-C-0010A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
19-C-0006Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator PhenotypeParticipants currently recruited/enrolled18-125 YearsNCI
19-C-0002A Phase II Study of M7824 in Subjects with Recurrent Respiratory PapillomatosisNo longer recruiting/follow-up only18-125 YearsNCI
18-C-0147Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0143A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior ChemotherapyCompleted Study; data analyses ongoing18-125 YearsNCI
18-C-0138An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.No longer recruiting/follow-up only18-125 YearsNCI
18-C-0137Phase II Clinical Trial of Sunitinib in Sarcomas of the Central Nervous SystemCompleted Study; data analyses ongoing18-125 YearsNCI
18-C-0136Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaCompleted Study; data analyses ongoing18-125 YearsNCI
18-C-0135Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationParticipants currently recruited/enrolled4-125 YearsNCI
18-C-0130PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's LymphomaNo longer recruiting/follow-up only18-125 YearsNCI
18-C-0126NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)No longer recruiting/follow-up only1-21 YearsNCI
18-C-0125A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple MyelomaNo longer recruiting/follow-up only18-73 YearsNCI
18-C-0122Phase 1B Study of Copanlisib in Combination with Nivolumab or with Nivolumab and IpilimumabParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0110Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell CancersParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0102Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)Participants currently recruited/enrolled18-125 YearsNCI
18-C-0097Phase II Study of Olaparib in Subjects with Malignant MesotheliomaCompleted Study; data analyses ongoing18-99 YearsNCI
18-C-0096A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, with Enzalutamide in Patients with Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentNo longer recruiting/follow-up only18-125 YearsNCI
18-C-0093Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment TrialsParticipants currently recruited/enrolled3-125 YearsNCI
18-C-0080Feasibility and Preliminary Efficacy of an Enhanced Mindfulness- Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled TrialParticipants currently recruited/enrolled5-125 YearsNCI
18-C-0078A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)Participants currently recruited/enrolled18-125 YearsNCI
18-C-0076Bicalutamide With or Without Metformin for Biochemical Recurrence in Prostate Cancer Patients (BIMET-1)Completed Study; data analyses ongoing18-85 YearsNCI
18-C-0062Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsCompleted Study; data analyses ongoing2-30 YearsNCI
18-C-0061A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination with Gemcitabine in Adults with Previously Treated Advanced Adenocarcinoma of the PancreasCompleted Study; data analyses ongoing18-125 YearsNCI
18-C-0059Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI
18-C-0058A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy FemalesParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0056Phase II Trial of M7824 in Subjects with HPV Associated MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI
18-C-0049A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic CancerClinical hold/Recruitment or enrollment suspended18-70 YearsNCI
18-C-0043Generation of Cancer Antigen-Specific T-cells from Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future TherapyCompleted Study; data analyses ongoing15-125 YearsNCI
18-C-0038Long Term Follow-up (LTFU) of Participants Treated with GSK Adoptive Cell TherapiesNo longer recruiting/follow-up only4-125 YearsNCI
18-C-0034A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaNo longer recruiting/follow-up only18-125 YearsNCI
18-C-0033Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory CancersParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0028A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy RadiotherapyParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0026A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (BALL)Clinical hold/Recruitment or enrollment suspended1-21 YearsNCI
18-C-0024A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the LiverParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0017Profiling of Radiological Factors in Treatment and Outcomes in Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0014Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI
18-C-0008Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus ObservationParticipants currently recruited/enrolled18-125 YearsNCI
18-C-0005Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0176Phase Ib Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent MalignanciesCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0175CC-4047-BRN-001: A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain TumorsCompleted Study; data analyses ongoing3-20 YearsNCI
17-C-0174Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0164A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin s LymphomaNo longer recruiting/follow-up only18-125 YearsNCI
17-C-0158A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer PatientsEnrolling by Invitation18-125 YearsNCI
17-C-0157A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)Participants currently recruited/enrolled18-125 YearsNCI
17-C-0156Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer InstituteParticipants currently recruited/enrolled18-120 YearsNCI
17-C-0153Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior RadiotherapyParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0149Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell LymphomasNo longer recruiting/follow-up only18-125 YearsNCI
17-C-0140Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, and Esophageal Carcinomas, or Pleural MesotheliomasParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0137Leukapheresis for CAR-Therapy ManufacturingParticipants currently recruited/enrolled3-39 YearsNCI
17-C-0127Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0125Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin LymphomasParticipants currently recruited/enrolled12-125 YearsNCI
17-C-0117A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0115Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic RadiosurgeryParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0113A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsClinical hold/Recruitment or enrollment suspended18-70 YearsNCI
17-C-010918F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0105Prospective Study of Clonal Evolution in Follicular LymphomaParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0102Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS CancersParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0100Collection of Malignant Ascites, Pleural Fluid, and Blood from Patients with Solid TumorsEnrolling by Invitation18-125 YearsNCI
17-C-0092A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal CancerNo longer recruiting/follow-up only18-125 YearsNCI
17-C-0090DART: Dual Anti-CTLA-4 And Anti-Pd-1 Blockade In Rare TumorsParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0089Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0088A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney CancerCompleted Study; data analyses ongoing12-125 YearsNCI
17-C-0087Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0086An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell CarcinomaNo longer recruiting/follow-up only18-125 YearsNCI
17-C-0082A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination with Capecitabine and Oxaliplatin (CAPOX) in Subjects with Advanced Biliary Tract Carcinoma (BTC)No longer recruiting/follow-up only18-125 YearsNCI
17-C-0074A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part SarcomaParticipants currently recruited/enrolled2-125 YearsNCI
17-C-0070Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal CytologyParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0066A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based ChemotherapyParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0061Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0057A Randomized Phase II Trial of Standard of Care Alone or in Combination with Ad-CEA Vaccine and Avelumab in Patients with Previously Untreated Metastatic or Unresectable Colorectal CancerNo longer recruiting/follow-up only18-125 YearsNCI
17-C-0052Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor, alone or in combination with Oral Decitabine/Tetrahydrouridine asSecond Line Therapy for Non-Small Cell Lung CancerCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0049A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar RhabdomyosarcomaParticipants currently recruited/enrolled2-125 YearsNCI
17-C-0048Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell LymphomasNo longer recruiting/follow-up only18-73 YearsNCI
17-C-0045A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and LymphomasParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0044Prospective Evaluation and Molecular Profiling in Patients with Gastric TumorsParticipants currently recruited/enrolled2-125 YearsNCI
17-C-0043Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric CancerParticipants currently recruited/enrolled2-125 YearsNCI
17-C-0038A Phase Ib Open Label, Dose Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0037Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaParticipants currently recruited/enrolled18-125 YearsNCI
17-C-0034A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)Participants currently recruited/enrolled18-125 YearsNCI
17-C-0028A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic LeukemiaParticipants currently recruited/enrolled2-21 YearsNCI
17-C-0027Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell TransplantationParticipants currently recruited/enrolled4-125 YearsNCI
17-C-0023A Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy Subjects with Non-Small Cell Lung CancerCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0012Phase I Study of a Combination of MM-398 and Veliparib in Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0011Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0009Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and GlioblastomaCompleted Study; data analyses ongoing18-125 YearsNCI
17-C-0007Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0171Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0160A Phase II Study of Avelumab in Subjects with Recurrent Respiratory PapillomatosisNo longer recruiting/follow-up only18-99 YearsNCI
16-C-0154A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated CancersParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0152Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms with Pleuropulmonary MetastasesParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0151Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous SystemParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0138Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell TherapyParticipants currently recruited/enrolled18-99 YearsNCI
16-C-0135A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)Participants currently recruited/enrolled18-125 YearsNCI
16-C-0131A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing CancersClinical hold/Recruitment or enrollment suspended18-70 YearsNCI
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0127A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 with or without Nab-Paclitaxel (Abraxane) in Patients with Malignant MesotheliomaCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0121A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0107A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate CancersParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0097Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine GliomaParticipants currently recruited/enrolled2-21 YearsNCI
16-C-0094A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)Participants currently recruited/enrolled18-99 YearsNCI
16-C-0092A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)No longer recruiting/follow-up only18-125 YearsNCI
16-C-0088A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary PeritoneaCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0087Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI
16-C-0081A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent GlioblastomaParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0076Prospective Screening for Patient Specific Genotypes and Phenotypes that Influence Drug Dosing and Trial Selection in Cancer PatientsEnrolling by Invitation18-125 YearsNCI
16-C-0073A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0066Phase I Study of Pembrolizumab in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0062A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)Completed Study; data analyses ongoing18-125 YearsNCI
16-C-0061Biospecimen Procurement for Genitourinary Malignancies Branch Immunotherapy ProtocolsParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0060A Phase 1b/2 Study of alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell TransplantationParticipants currently recruited/enrolled18-99 YearsNCI
16-C-0054T Cells Expressing a Fully-human Anti- CD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesNo longer recruiting/follow-up only18-73 YearsNCI
16-C-0048Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate CancerNo longer recruiting/follow-up only18-125 YearsNCI
16-C-0047A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi SarcomaParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0043Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0035Prostvac in Patients with Biochemically Recurrent Prostate CancerNo longer recruiting/follow-up only18-125 YearsNCI
16-C-0034A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)without Prior Bevacizumab Exposure and (B) after Failing Prior BevacizumabCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0027A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma using Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes Plus IL-2 either Alone or Following the Administration of PembrolizumabClinical hold/Recruitment or enrollment suspended16-70 YearsNCI
16-C-0025A Phase 1 Study of bb2121 in BCMA-Expressing Multiple MyelomaNo longer recruiting/follow-up only18-125 YearsNCI
16-C-0011A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade GliomasCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0010Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer TissueParticipants currently recruited/enrolled18-125 YearsNCI
16-C-0009Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center TrialCompleted Study; data analyses ongoing18-125 YearsNCI
16-C-0003Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesParticipants currently recruited/enrolled4-75 YearsNCI
15-C-0205Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active SurveillanceCompleted Study; data analyses ongoing18-99 YearsNCI
15-C-0204Clinical and Laboratory Analysis of Familial CancerCompleted Study; data analyses ongoing10-125 YearsNCI
15-C-0200Molecular Analysis for Therapy Choice (MATCH) (EAY131)Participants currently recruited/enrolled18-120 YearsNCI
15-C-0195Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)Participants currently recruited/enrolled5-125 YearsNCI
15-C-0179A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indicaNo longer recruiting/follow-up only18-125 YearsNCI
15-C-0168A Phase I Trial of Pomalidomide for Children with Recurrent, Progressive or Refractory CNS TumorsCompleted Study; data analyses ongoing3-21 YearsNCI
15-C-0160A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary TumorsParticipants currently recruited/enrolled18-125 YearsNCI
15-C-0157Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI
15-C-0150A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI
15-C-0145Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI
15-C-0142Acceptance and Commitment Training for Adolescents and Young Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical TrialCompleted Study; data analyses ongoing16-59 YearsNCI
15-C-0141Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR-T Cell StudiesEnrolling by Invitation18-125 YearsNCI
15-C-0138Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GlioblastomaCompleted Study; data analyses ongoing18-125 YearsNCI
15-C-0124Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate CancerNo longer recruiting/follow-up only18-125 YearsNCI
15-C-0116Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid TumorsClinical hold/Recruitment or enrollment suspended18-125 YearsNCI
15-C-0110A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 [(hetIL-15) (IL15 / sIL-15Ra)] alone and in combination with PDR001 in Adults with Metastatic CancersCompleted Study; data analyses ongoing18-125 YearsNCI
15-C-0105Randomized Controlled Trial of Total Thyroidectomy with and without Prophylactic Central Neck Lymph Node Dissection in Patients with Low-risk Papillary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI
15-C-0099A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine TumorsCompleted Study; data analyses ongoing18-100 YearsNCI
15-C-0093Phase I/II Trial of PLX3397 in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)Participants currently recruited/enrolled3-35 YearsNCI
15-C-0087Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer PatientsParticipants currently recruited/enrolled18-125 YearsNCI
15-C-0086Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatiric Patients with Refractory Solid TumorsParticipants currently recruited/enrolled12-120 YearsNCI
15-C-0078Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAsNo longer recruiting/follow-up only18-65 YearsNCI
15-C-0076A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.No longer recruiting/follow-up only18-99 YearsNCI
15-C-0075A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate CancerParticipants currently recruited/enrolled18-99 YearsNCI
15-C-0067A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-125 YearsNCI
15-C-0046Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) TumorsNo longer recruiting/follow-up only18-125 YearsNCI
15-C-0029Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI
15-C-0028Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical TrialsEnrolling by Invitation1-99 YearsNCI
15-C-0027A Pilot Study of Immune Checkpoint Inhibition (Durvalumab with or without Tremelimumab) in Combination with Radiation Therapy in Patients with Unresectable Pancreatic CancerCompleted Study; data analyses ongoing18-125 YearsNCI
15-C-0019The Impact of Ras/MAPK Signaling Pathway-Targeted Therapies on Neurocognitive Functioning in Individuals with NF1Completed Study; data analyses ongoing4-99 YearsNCI
14-C-0163Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic AnalysisCompleted Study; data analyses ongoing10-125 YearsNCI
14-C-0161Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic SyndromesParticipants currently recruited/enrolled18-125 YearsNCI
14-C-0157Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS LymphomaParticipants currently recruited/enrolled18-125 YearsNCI
14-C-0156A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerNo longer recruiting/follow-up only18-125 YearsNCI
14-C-0131A Phase II, Open-Label Study in Patients With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and TrametinibNo longer recruiting/follow-up only18-125 YearsNCI
14-C-0128Collection of Pharmacokinetic Samples from Patients with Unanticipated Response, Significant Toxicity or Concern of Future ToxicityParticipants currently recruited/enrolled2-125 YearsNCI
14-C-0116A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain TumorsParticipants currently recruited/enrolled8-125 YearsNCI
14-C-0105Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsParticipants currently recruited/enrolled18-125 YearsNCI
14-C-0104A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative RegimenClinical hold/Recruitment or enrollment suspended18-70 YearsNCI
14-C-0079An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults with Cancer and Other Chronic IllnessesParticipants currently recruited/enrolled18-125 YearsNCI
14-C-0059A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid TumorsCompleted Study; data analyses ongoing1-35 YearsNCI
14-C-0056Collection of Blood from Patients with Ovarian, Primary Peritoneal or Fallopian Tube CancerCompleted Study; data analyses ongoing18-125 YearsNCI
14-C-0052A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and AldesleukinCompleted Study; data analyses ongoing18-70 YearsNCI
14-C-0037A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerNo longer recruiting/follow-up only18-125 YearsNCI
14-C-0036A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC[TM] Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 ICompleted Study; data analyses ongoing18-125 YearsNCI
14-C-0022A Phase II Study for Metastatic Melanoma using High Dose Chemotherapy Preparative Regimen followed by Cell Transfer Therapy Using Tumor Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment ArmNo longer recruiting/follow-up only18-70 YearsNCI
14-C-0015Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsCompleted Study; data analyses ongoing18-120 YearsNCI
14-C-0007Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults with Desmoid Tumors/Aggressive FibromatosisNo longer recruiting/follow-up only18-120 YearsNCI
14-C-0004A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell LeukemiaParticipants currently recruited/enrolled18-125 YearsNCI
14-C-0001Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompleted Study; data analyses ongoing18-125 YearsNCI
13-C-0214A Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY-ESO-1 Murine TCR-Gene Engineered LymphocytesCompleted Study; data analyses ongoing15-70 YearsNCI
13-C-0202Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing CancersParticipants currently recruited/enrolled2-125 YearsNCI
13-C-0176Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid TumorsParticipants currently recruited/enrolled2-125 YearsNCI
13-C-0175A Phase II Protocol for Subjects with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radio-sensitizing Chemotherapy following a Thorough Transurethral Surgical Re-StagingCompleted Study; data analyses ongoing18-125 YearsNCI
13-C-0153A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-Metastatic Castration Sensitive Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI
13-C-0152A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid TumorsCompleted Study; data analyses ongoing2-25 YearsNCI
13-C-0146A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate CancerNo longer recruiting/follow-up only18-125 YearsNCI
13-C-0132Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC SyndromeParticipants currently recruited/enrolled8-70 YearsNCI
13-C-0131Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer and Patients Treated with an Adoptive Cellular TherapyParticipants currently recruited/enrolled18-125 YearsNCI
13-C-0128Collection of Saliva and/or Peripheral Blood from Healthy Volunteers for ResearchCompleted Study; data analyses ongoing18-99 YearsNCI
13-C-0119Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided BiopsiesParticipants currently recruited/enrolled18-125 YearsNCI
13-C-0118A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and LymphomasParticipants currently recruited/enrolled18-125 YearsNCI
13-C-0105Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsCompleted Study; data analyses ongoing18-120 YearsNCI
13-C-0095A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI
13-C-0044A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue SarcomaNo longer recruiting/follow-up only18-120 YearsNCI
13-C-0032A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid TumorsCompleted Study; data analyses ongoing18-120 YearsNCI
13-C-0016A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults with Tumors with 1-3+ HER2/neu ExpressionCompleted Study; data analyses ongoing18-99 YearsNCI
13-C-0006Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)Participants currently recruited/enrolled18-125 YearsNCI
12-C-0206Understanding the Perceived Influence of Childhood Cancer and NF1 on the Parents' Marital/Partner Relationship: A Descriptive StudyCompleted Study; data analyses ongoing18-125 YearsNCI
12-C-0205A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI
12-C-0197A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHDCompleted Study; data analyses ongoing18-75 YearsNCI
12-C-0196A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI
12-C-0193Lymphoid Malignancies and Precursors: Tissue Acquisition ProtocolParticipants currently recruited/enrolled18-125 YearsNCI
12-C-0178Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid CarcinomaParticipants currently recruited/enrolled0-125 YearsNCI
12-C-0175Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic TargetsCompleted Study; data analyses ongoing18-99 YearsNCI
12-C-0160Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults with Chronic Illness and their ParentsCompleted Study; data analyses ongoing18-34 YearsNCI
12-C-0118A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic ChemotherapyNo longer recruiting/follow-up only18-100 YearsNCI
12-C-0113A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults with Metastatic CancersCompleted Study; data analyses ongoing18-125 YearsNCI
12-C-0112Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell MalignanciesCompleted Study; data analyses ongoing1-30 YearsNCI
12-C-0107Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot StudyNo longer recruiting/follow-up only18-125 YearsNCI
12-C-0081Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerNo longer recruiting/follow-up only18-125 YearsNCI
12-C-0079A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI
12-C-0074Mobilization and Collection of Autologous Hematopoietic Progenitor Cell (HPC) for Transplantation (AHCT) for Plasma Cell Myeloma (PCM)Completed Study; data analyses ongoing18-75 YearsNCI
12-C-0068A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host-DiseaseCompleted Study; data analyses ongoing12-125 YearsNCI
12-C-0066Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
12-C-0047A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIVNo longer recruiting/follow-up only18-125 YearsNCI
12-C-0009Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients with Refractory Advanced Solid TumorsCompleted Study; data analyses ongoing18-120 YearsNCI
12-C-0003Phase I/II Trial of Yttrium-90-labeled Daclizumab (anti-CD25) Radioimmunotherapy with High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI
11-C-0255Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni SyndromeParticipants currently recruited/enrolled0-100 YearsNCI
11-C-0247A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer PatientsCompleted Study; data analyses ongoing18-100 YearsNCI
11-C-0242Collection of Blood from Patients with Cancer for Analysis of Genetic Differences in Drug DispositionParticipants currently recruited/enrolled18-125 YearsNCI
11-C-0232A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination with mTOR Inhibitor RAD001 (Everolimus) in Patients with Relapsed Multiple Myeloma or LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI
11-C-0225First In-Human Phase I Trial of NHS-IL12 in Patients with Metastatic Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI
11-C-0220Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted TherapiesParticipants currently recruited/enrolled18-125 YearsNCI
11-C-0200A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease ProgressionNo longer recruiting/follow-up only16-125 YearsNCI
11-C-0190Collection of Tissue Blocks or Slides from Patients with CancerParticipants currently recruited/enrolled18-125 YearsNCI
11-C-0161A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)No longer recruiting/follow-up only2-18 YearsNCI
11-C-0158MR Image Guided Focal Therapy in Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI
11-C-0140A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
11-C-0136Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging EvaluationCompleted Study; data analyses ongoing2-55 YearsNCI
11-C-0132Understanding the Psychosocial Needs of Parents Who Have Lost a Child to CancerCompleted Study; data analyses ongoing18-99 YearsNCI
11-C-0123Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction with 12 Gy Total Body Irradiation (TBI)No longer recruiting/follow-up only18-66 YearsNCI
11-C-0112Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal CancerParticipants currently recruited/enrolled18-125 YearsNCI
11-C-0096Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI
11-C-0073A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation from Related or Matched Unrelated Donors in Pediatric Patients with Hematologic MalignanciesCompleted Study; data analyses ongoing4-35 YearsNCI
11-C-0061Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI
11-C-0060Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic DysfunctionCompleted Study; data analyses ongoing18-125 YearsNCI
11-C-0034DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyParticipants currently recruited/enrolled0-100 YearsNCI
11-C-0033Extended Follow-up of High Ovarian Cancer Risk Cohort from 02-C-0268 (GOG-199)Completed Study; data analyses ongoing18-100 YearsNCI
10-C-0219A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-grade GliomasCompleted Study; data analyses ongoing1-21 YearsNCI
10-C-0201Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 DeficiencyParticipants currently recruited/enrolled18-40 YearsNCI
10-C-0181Phase 1 Dose-Escalation Study of Bruton s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI
10-C-0174Related and Unrelated Donor Hematopoietic Stem Cell Transplant of DOCK8 DeficiencyParticipants currently recruited/enrolled2-60 YearsNCI
10-C-0166A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabClinical hold/Recruitment or enrollment suspended18-70 YearsNCI
10-C-0114A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerNo longer recruiting/follow-up only18-125 YearsNCI
10-C-0086Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological StudiesParticipants currently recruited/enrolled0-125 YearsNCI
10-C-0066Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer TreatmentParticipants currently recruited/enrolled18-125 YearsNCI
10-C-0056A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasCompleted Study; data analyses ongoing18-120 YearsNCI
10-C-0054Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell TransplantationParticipants currently recruited/enrolled18-75 YearsNCI
10-C-0052Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults with Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic LymphomaNo longer recruiting/follow-up only18-125 YearsNCI
10-C-0025Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaParticipants currently recruited/enrolled18-125 YearsNCI
10-C-0011Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasNo longer recruiting/follow-up only18-125 YearsNCI
09-C-0242Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsParticipants currently recruited/enrolled4-125 YearsNCI
09-C-0192Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaNo longer recruiting/follow-up only0-120 YearsNCI
09-C-0161Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by Invitation18-125 YearsNCI
09-C-0139A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate CancerCompleted Study; data analyses ongoing18-100 YearsNCI
09-C-0120An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated SkinCompleted Study; data analyses ongoing18-125 YearsNCI
09-C-0100A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology BranchParticipants currently recruited/enrolled18-125 YearsNCI
09-C-0082An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients with B-Cell LymphomaNo longer recruiting/follow-up only18-70 YearsNCI
09-C-0065Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI
09-C-0053Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)Enrolling by Invitation0-125 YearsNCI
09-C-0025Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI
09-C-0024A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young AdultsCompleted Study; data analyses ongoing12-26 YearsNCI
09-C-0019A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
09-C-0005Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual DiseaseParticipants currently recruited/enrolled18-125 YearsNCI
08-C-0214A Pilot Study to Evaluate Neuropsychological Outcome Measures and their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain MetastasesParticipants currently recruited/enrolled18-125 YearsNCI
08-C-0130A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform NeurofibromasCompleted Study; data analyses ongoing0-21 YearsNCI
08-C-0079Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1No longer recruiting/follow-up only0-125 YearsNCI
08-C-0020A Phase 2 Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
07-C-0195Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the TreaCompleted Study; data analyses ongoing18-74 YearsNCI
07-C-0121A Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal-Cell Carcinoma (PRC)Completed Study; data analyses ongoing18-125 YearsNCI
07-C-0110Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-Approved ProtocolsEnrolling by Invitation0-125 YearsNCI
07-C-0107A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men with Androgen Insensitive, Non-Metastatic (D0.5) Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI
07-C-0100Collection of Blood from Patients with Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI
06-HG-0134Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1Completed Study; data analyses ongoing20-99 YearsNCI
06-C-0219An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System TumorsCompleted Study; data analyses ongoing0-21 YearsNCI
06-C-0213Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)Participants currently recruited/enrolled0-110 YearsNCI
06-C-0150A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI
06-C-0014Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic MalignanciesParticipants currently recruited/enrolled2-125 YearsNCI
05-C-0252Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell LymphomasNo longer recruiting/follow-up only18-125 YearsNCI
05-C-0170Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance versus Observation in Untreated Mantle Cell Lymphoma with Microarray Profiling and ProteomicsNo longer recruiting/follow-up only18-100 YearsNCI
04-C-0281Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host DiseaseParticipants currently recruited/enrolled1-125 YearsNCI
04-C-0275Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease ActivityParticipants currently recruited/enrolled18-125 YearsNCI
04-C-0274Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic AgentsParticipants currently recruited/enrolled18-125 YearsNCI
04-C-0238A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal TumorsCompleted Study; data analyses ongoing18-125 YearsNCI
04-C-0232A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of RelapseCompleted Study; data analyses ongoing18-100 YearsNCI
04-C-0200Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for RecurrenceParticipants currently recruited/enrolled18-125 YearsNCI
04-C-0165Data Collection, Standard Care and Interventions in CCR, NCIEnrolling by Invitation0-125 YearsNCI
04-C-0102Hematologic Malignancy Biology StudyEnrolling by Invitation0-75 YearsNCI
03-C-0304Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell LymphomasCompleted Study; data analyses ongoing17-125 YearsNCI
03-C-0278A Comparative Study of Pediatric CNS Tumor Activity as Assessed by [18]F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging ([1]H-MRSI)Completed Study; data analyses ongoing1-21 YearsNCI
03-C-0277Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy ProtocolsEnrolling by Invitation18-125 YearsNCI
03-C-0066Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal CancerParticipants currently recruited/enrolled2-125 YearsNCI
02-C-0313Cancer Risk in Xeroderma Pigmentosum HeterozygotesParticipants currently recruited/enrolled0-99 YearsNCI
02-C-0268Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian CancerCompleted Study; data analyses ongoing19-100 YearsNCI
02-C-0212Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompleted Study; data analyses ongoing18-100 YearsNCI
02-C-0211Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaParticipants currently recruited/enrolled1-100 YearsNCI
02-C-0210Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node MalignancyParticipants currently recruited/enrolled1-100 YearsNCI
02-C-0179Biospecimen Acquisition from Human SubjectsParticipants currently recruited/enrolled18-125 YearsNCI
02-C-0178Multidisciplinary Etiologic Study of Familial Testicular CancerNo longer recruiting/follow-up only12-100 YearsNCI
02-C-0159The Birt Hogg-Dube Syndrome: Identification of the Disease Gene and Characterization of the Predisposition of Renal CancerParticipants currently recruited/enrolled2-125 YearsNCI
02-C-0077Characterization of High-Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression ProfileParticipants currently recruited/enrolled18-74 YearsNCI
02-C-0064Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation TherapyEnrolling by Invitation18-125 YearsNCI
02-C-0052Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History StudyParticipants currently recruited/enrolled0-125 YearsNCI
01-C-0129Eligibility Screening for the NIH Intramural Research Program Clinical ProtocolsEnrolling by Invitation0-125 YearsNCI
01-C-0038Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or CancerParticipants currently recruited/enrolled18-125 YearsNCI
01-C-0030Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated LymphomasNo longer recruiting/follow-up only18-125 YearsNCI
01-C-0009Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up StudyCompleted Study; data analyses ongoing18-100 YearsNCI
00-C-0133Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI
00-C-0078Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal VolunteersParticipants currently recruited/enrolled18-125 YearsNCI
00-C-0074Evaluation of Late Effects and Natural History of Disease in Patients Treated with RadiotherapyParticipants currently recruited/enrolled18-125 YearsNCI
99-C-0128Evaluation for NCI Surgery Branch Clinical Research ProtocolsParticipants currently recruited/enrolled18-70 YearsNCI
99-C-0099Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or TrichothiodystrophyParticipants currently recruited/enrolled0-125 YearsNCI
97-C-0147Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant DiseasesParticipants currently recruited/enrolled2-125 YearsNCI
97-C-0143Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 InfectionParticipants currently recruited/enrolled18-125 YearsNCI
97-C-0040EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients with AIDS-Associated LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI
96-C-0071Follow-up for Patients Previously Enrolled on the Center for Cancer Research ProtocolsNo longer recruiting/follow-up only0-125 YearsNCI
94-C-0074Treatment and Natural History Study of Lymphomatoid GranulomatosisParticipants currently recruited/enrolled12-125 YearsNCI
93-C-0133Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's LymphomaNo longer recruiting/follow-up only12-125 YearsNCI
89-C-0086Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersParticipants currently recruited/enrolled2-125 YearsNCI
83-C-0022Psychological Benefits of a Normalized Camping Experience for Children with CancerParticipants currently recruited/enrolled7-25 YearsNCI
79-C-0111The Treatment of Stage I and II Carcinoma of the Breast with Mastectomy and Axillary Dissection versus Excisional Biopsy, Axillary Dissection, and Definitive IrradiationCompleted Study; data analyses ongoing18-125 YearsNCI
78-C-0039Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of CancerNo longer recruiting/follow-up only1-110 YearsNCI